Tandem Diabetes Care, a medical device company, on Monday
announced that the U.S. Food and Drug Administration (FDA) has granted the
clearance to market the t:flex Insulin Pump.
At 480 units, the insulin reservoir of the t:flex Pump has
the largest capacity currently available in the United States.
"In recognizing that one size does not fit all, the t:flex
Pump was developed using Tandem's proprietary technology platform to bring
t:slim's benefits to people with greater insulin needs. This first expansion of
our product portfolio reflects our ongoing commitment to deliver user-friendly
products that address unmet needs in the diabetes community," said Kim
Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care.
People with diabetes require different amounts of insulin
based on their level of insulin sensitivity. The t:flex is designed for people
who require more than 100 units of U-100 insulin per day. The pump offers
people with greater insulin needs the benefits of pump therapy without the
frequent reservoir changes required by 200- and 300-unit capacity pumps. It
incorporates the same slim design, advanced Micro-Delivery technology, and
simple-to-use, touch-screen interface as the t:slim Insulin Pump.
The t:flex is expected to launch in the US in the second
quarter of 2015.
Diabetes is a chronic, life-threatening disease that affects
more than 29 million people in the United States. More than 3 million people
in the United States require daily administration of insulin and are candidates
for pump therapy. Around 400,000 Americans with type 1 diabetes use an insulin
pump, or approximately 27% of the type 1 diabetes population. In addition,
approximately 75,000 Americans with typeá2 diabetes use an insulin pump, a
small fraction of the typeá2 diabetes population.
Recent studies show that insulin pump therapy reduces
average blood glucose levels and overall insulin needs in people with type 2
diabetes compared with standard therapy using multiple daily injections (2).
According to a research, two-thirds of endocrinologists cited limited capacity
as the number one barrier to insulin pump adoption for people with type 2
diabetes who are insulin dependent.